Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study
unknown
📅 Published: 2026-02-09 08:25
📰 Source: Benzinga
📝 Words: 25
📝 Article Content
Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.
📄 Summary
Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-02-12 12:08:00
Updated At:
2026-02-12 12:08:00
Scraping Job ID:
N/A
Stock Mentions:
AMP - Ameriprise Financial Inc.
Relevance: N/A